Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $1.6 million.

  • Artiva Biotherapeutics' Share-based Compensation fell 1447.3% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 1984.49%. This contributed to the annual value of $7.0 million for FY2024, which is 103.5% down from last year.
  • According to the latest figures from Q3 2025, Artiva Biotherapeutics' Share-based Compensation is $1.6 million, which was down 1447.3% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Artiva Biotherapeutics' Share-based Compensation peaked at $2.2 million during Q4 2024, and registered a low of $1.4 million during Q3 2023.
  • Over the past 3 years, Artiva Biotherapeutics' median Share-based Compensation value was $1.5 million (recorded in 2025), while the average stood at $1.7 million.
  • As far as peak fluctuations go, Artiva Biotherapeutics' Share-based Compensation skyrocketed by 5689.66% in 2024, and later crashed by 1447.3% in 2025.
  • Over the past 3 years, Artiva Biotherapeutics' Share-based Compensation (Quarter) stood at $1.4 million in 2023, then surged by 56.9% to $2.2 million in 2024, then fell by 25.32% to $1.6 million in 2025.
  • Its Share-based Compensation stands at $1.6 million for Q3 2025, versus $1.5 million for Q2 2025 and $2.1 million for Q1 2025.